Cidara's antimicrobial reunion

Seasoned antiinfectives team at Cidara aiming to disrupt antifungal market

Investors in Cidara Therapeutics Inc.'s $32 million series A round are hoping for a repeat performance by a management team with a track record of exits in the infectious disease space.

5AM Ventures led the round and was joined

Read the full 389 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE